Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Author Archives: Warren Woessner
Guidance on Biosimilar Development Finalized by FDA
Bloomberg BNA posted an overview of the FDA’s guide on biosimilar development. Read the overview here.
Posted in Biosimilars
Leave a comment
In re NuVasive, Inc. – Explain Yourself!
In re NuVasive Emphasizes the Importance of Reasoning in the Obviousness Question. Since KSR, 127 S.Ct. 1727 (2007), repudiated as “rigid and mandatory” the Federal Circuit “rule” for obviousness – that the prior art must provide a teaching, suggestion or … Continue reading
Posted in Obviousness
1 Comment
USPTO Holds First Roundtable on “Subject Matter Eligibility Guidelines”
On November 14th, the PTO hosted a roundtable discussion in Alexandria on s. 101 issues in which both industry reps and practitioners were invited to dissect the current Office guidelines. The structure was unique as there were 33 invited speakers … Continue reading
PTO Schedules s. 101 Roundtables
At 81 Fed. Reg. 71485, The PTO has scheduled two roundtables at the PTO to receive feedback from the IP community, particularly on the Examples that were promulgated in May. The first roundtable will be on November 14th from 1:00-5:00 … Continue reading